AlbionVentures

Dexela

Albion Ventures LLP first invested in Dexela in May 2006. Dexela had developed technology to optimise the use of low-dose X-rays for 3-Dimensional imaging, focused initially on the detection of breast cancer. At the time the Company had low revenues and 6 employees.

Following investment Dexela built and trialled its proprietary X-Ray imaging system. It also developed a portfolio of software modules for imaging reconstruction and visualisation. Further investment in 2008 allowed the company to acquire a detector company, enabling the development of its own range of flat-panel CMOS-based digital detectors, optimised for use in low-dose X-Ray applications. Following launch in 2009, these detectors quickly became market leading, leading to rapid, profitable growth.

The Company was sold to Perkin Elmer, a US-based global healthcare technology company, in June 2011. Albion Ventures invested £2.6 million in the Company, and expects to achieve up to 3x return on investment.

Ed Bullard, CEO of Dexela, said, “Continued investment over the years from Albion has been fundamental to the Company’s success. Albion’s understanding of the healthcare sector was an important reason for selecting them as investors and the business benefited substantially from Albion’s expertise and knowledge of the sector.”